e-learning
resources
Berlin 2008
Tuesday, 07.10.2008
Imaging and measurement techniques in the evaluation of pulmonary embolism, COPD and pleural diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The importance of radiological findings to distinguish benign and malignant pleural diseases
G. Ak, M. Metintas, H. Yildirim, S. Arslan, S. Erginel, F. Alatas, S. Metintas (Eskisehir, Turkey)
Source:
Annual Congress 2008 - Imaging and measurement techniques in the evaluation of pulmonary embolism, COPD and pleural diseases
Session:
Imaging and measurement techniques in the evaluation of pulmonary embolism, COPD and pleural diseases
Session type:
E-Communication Session
Number:
4299
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Ak, M. Metintas, H. Yildirim, S. Arslan, S. Erginel, F. Alatas, S. Metintas (Eskisehir, Turkey). The importance of radiological findings to distinguish benign and malignant pleural diseases. Eur Respir J 2008; 32: Suppl. 52, 4299
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Imaging of complicated pneumonia: what is new?
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Radiologic manifestations of primary pleural tumors
Source: Annual Congress 2010 - Vascular and solitary lesions
Year: 2010
The use of immunocytochemistry to diagnose the etiology of malignant pleural effusion.
Source: International Congress 2018 – Mesothelioma and pleural malignancy: investigations and management
Year: 2018
Diagnostic problems in benign and malignant pleural effusions
Source: Annual Congress 2007 - PG16 - Management of pleural problems in your practice today
Year: 2007
Pathological diagnosis of malignant pleural mesothelioma
Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases
Year: 2020
The radiologic evidance in distinguishing the pleural mesothelioma from the pleural metastatic adenocarcinoma
Source: Eur Respir J 2006; 28: Suppl. 50, 93s
Year: 2006
Epidemiology, etiology, prognosis and presentation of malignant pleural mesothelioma
Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases
Year: 2020
A rare case of malignant pleural mesothelioma presenting with multiple metastatic pulmonary nodules
Source: Annual Congress 2011 - Pleural and mediastinal malignancies: management and rare clinical cases
Year: 2011
The role of 99m-Tc-Depreotide scintigraphy in discriminating between malignant and benign pulmonary nodules
Source: Eur Respir J 2005; 26: Suppl. 49, 492s
Year: 2005
Sonographic echogenic swirling pattern in patients with malignancies: a useful diagnostic predictor for malignant pleural effusions
Source: Annual Congress 2008 - Imaging and measurement techniques in the evaluation of pulmonary embolism, COPD and pleural diseases
Year: 2008
Prognostic significance of pretreatment clinical and laboratory characteristics in patients with diffuse malignant pleural mesothelioma
Source: Eur Respir J 2006; 28: Suppl. 50, 784s
Year: 2006
A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions
Source: Eur Respir J 2013; 41: 18-24
Year: 2013
The management of benign non-infective pleural effusions
Source: Eur Respir Rev 2016; 25: 303-316
Year: 2016
A case report: surprising diagnosis of malignant mesothelioma in a patient with malignant pleural effusion, mediastinal lymphoma and intestinal carcinoma in situ
Source: Eur Respir J 2004; 24: Suppl. 48, 527s
Year: 2004
Dealing with diagnosis of benign and malignant pleural effusions
Source: Annual Congress 2010 - PG5 Postgraduate Course: Interventional thoracoscopy
Year: 2010
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Source: Guideline 2020
Year: 2020
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Source: Eur Respir J, 55 (6) 1900953; 10.1183/13993003.00953-2019
Year: 2020
Comparison of telomerase activity in malignant and benign pleural effusions
Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura
Year: 2011
Diagnosis and staging of malignant pleural mesothelioma
Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases
Year: 2020
Outcomes of cytology positive malignant pleural effusions; do certain malignancies predispose patients to trapped lung?
Source: International Congress 2019 – Novel approaches to pleural effusion: should I change my practice?
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept